References
- Karim A. Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system. Angiology 1983; 34: 11–22
- Shaw J. E. Development of transdermal therapeutic systems. Drug Dev. Ind. Pharm. 1983; 9: 579–603
- Gerardin A., Hirtz J., Frankenhauser P., Moppert J. Achievement of sustained plasma concentrations of nitroglycerin in man by a transdermal therapeutic system. Academy of Pharmaceutical Sciences, Orlando, FL 1981; 84, Abst. 26
- Keshary P. R., Huang Y. C., Chien Y. W. Mechanism of transdermal controlled nitroglycerin administration, (III) Control of skin permeation rate and optimization. Drug Dev. Ind. Pharm. 1985; 11: 1213–1253
- Keshary P. R., Chien Y. W. Mechanism of transdermal controlled nitroglycerin administration. (II) Assessment of rate-controlling steps. Drug Dev. Ind. Pham. 1984; 10: 1663–1699
- Langguth P., Spahn H., Mutschler E. Variations of in vitro nitroglycerine permeation through human epidermis. Pharm. Res. 1986; 3: 61–63
- Noonan P. K., Gonzalez M. A., Benet L. Z., Williams R. L., Lin E. Pharmacokinetics of transdermal nitroglycerin in Japanese volunteers measuring nitroglycerin and its 1,2- and 1,3dinitrate metabolites, abstracts. Acad. Pharm. Sci. 1986; 16(1)
- Noonan P. K., Gonzalez M. A., Ruggirello D., Tomlinson J., Babcock-Atkinson E., Ray M., Golub A., Cohen A. Relative bioavailability of a new transdermal nitroglycerin delivery system. J. Pharm. Sci. 1986; 75: 688–691